This product is a nitroimidazole derivative that can inhibit the redox reaction of amoeba and break the nitrogen chain of the protozoa. It has a killing effect on histolytica and a strong killing effect on trichomonas. It has a killing effect on anaerobic microorganisms, interferes with the growth and reproduction of bacteria, and eventually kills bacteria.

This product is a nitroimidazole derivative that can inhibit the redox reaction of amoeba and break the nitrogen chain of the protozoa. In vitro tests have shown that when the drug concentration is 1-2 mg/L, the histolytica can undergo morphological changes in 6-20 hours and all are killed within 24 hours. When the concentration is 0.2 mg/L, the histolytica can be killed within 72 hours. This product has a strong effect of killing trichomonas, and its mechanism is unknown. Metronidazole has a killing effect on anaerobic microorganisms, and the metabolites generated when it is reduced in the human body also have anti-anaerobic effects, inhibiting the synthesis of bacterial deoxyribonucleic acid, thereby interfering with the growth and reproduction of bacteria, and ultimately causing bacterial death. Metronidazole is carcinogenic to some animals.

This product is a quinolone antibacterial drug, which has antibacterial effects on Gram-negative bacteria, such as Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Serratia, Salmonella typhi, Shigella, Pseudomonas aeruginosa, etc. This product acts on bacterial DNA gyrase, interfering with the synthesis of bacterial DNA, thereby causing bacterial death.

This product is a long-acting tricyclic antihistamine that competitively inhibits histamine H1 receptors and inhibits allergic symptoms caused by histamine. This product has no obvious anticholinergic and central nervous system inhibitory effects.

No specific pharmacological effects mentioned